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Retrospective review of ticagrelor and clopidogrel in adult patients in
the setting of dual antiplatelet therapy after percutaneous coronary
intervention in a community hospital
Jessica Hernandez, Pharm.D., Laura Neubauer, Pharm.D., Heidi Clarke, Pharm.D., BCCCP, Radhan B. Gopalani, Pharm.D., BCPS, Marcus E. St. John, M.D., FACC, FSCAI
Baptist Hospital of Miami, Department of Pharmacy; Miami, FL

BACKGROUND
•
•

•

•

•

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is
standard of care after percutaneous coronary intervention (PCI)1,2,4.
Ticagrelor is a newer/more potent P2Y12 inhibitor that is preferred
over clopidogrel due to its enhanced pharmacokinetic properties
and superior clinical outcomes3,5. This agent is limited, however, by
its high cost, increased risk of bleeding and BID dosing.
Between 2008-2016, patient non-adherence nearly tripled when
ticagrelor and prasugrel gained FDA approval and their use began to
increase6.
De-escalation of P2Y12 inhibitor therapy (transitioning from a more
potent agent to a less potent one, i.e. ticagrelor  clopidogrel) is a
strategy that provides patients with the more effective therapy
when risk of restenosis is at its highest, while mitigating the risk of
non-adherence secondary to cost and BID dosing in the long term.
De-escalation can be classified according to when it occurs relative
to initiation of P2Y12 inhibitor therapy:
Acute

(< 24 h)

•

Early

(1d <30 d)

Late

(30d  1 yr)

The purpose of this project is to retrospectively review the use of
ticagrelor and clopidogrel in adult patients following stent placement
and to observe the incidence of de-escalation over a 6 month period at
Baptist Hospital of Miami.

METHODS
Single-center, retrospective chart review of patients receiving DAPT
after PCI at Baptist Hospital between January 1st 2019 and June 30th
2019
• Inclusion Criteria:
• Patients ≥ 18 years of age
• Received aspirin plus ticagrelor or clopidogrel
• Exclusion Criteria:
• P2Y12 inhibitor prior to admission
• Contraindications to the use of a P2Y12 inhibitor
• Aspirin allergy
• Pregnancy
• Primary Outcomes:
• # of patients receiving ticagrelor or clopidogrel
• # of patients who were de-escalated from ticagrelor to
clopidogrel

•

Baseline Demographics (N=164)
64 (35 – 91)

Gender – male, n (%)

108 (65.9)

STEMI, n (%)

67 (40.6)

NSTEMI, n (%)

97 (59.4)

Concomitant aspirin use

164 (100)

•
•
•

Number of Patients Receiving
Ticagrelor vs Clopidogrel
Clopidogrel

•

Ticagrelor

73% of patients were started on ticagrelor for DAPT after PCI
• Of the 44 patients who received clopidogrel, 77% were treated for
NSTEMI
Of the 120 patients who received ticagrelor, 18 patients were de-escalated to
clopidogrel
Most common reasons for de-escalation were bleed risk and lack of insurance
15% of patients started on ticagrelor were de-escalated to clopidogrel
• 50% were de-escalated with a 300 mg loading dose
• 39% were de-escalated with a 75 mg dose
• 11% were de-escalated with a 600 mg loading dose
The average time from the last dose of ticagrelor to the first dose of clopidogrel in
patients who were de-escalated was ~11 hrs

LIMITATIONS

(> 1 yr)

An expert consensus published in 2017 outlines how this switch
should occur, including the recommendation to administer the first
dose of clopidogrel 24 hours after ticagrelor is discontinued,
regardless of when de-escalation occurs. Based on bleed risk, a
clopidogrel dose of 75 mg or a 300-600 mg loading dose is
recommended7.

DISCUSSION

Mean age, years (range)

Very late

PURPOSE

•

RESULTS RESULTS

•
•
•

120
(73%)

44
(27%)

Small sample size
Unable to justify the reason for selected clopidogrel dose for de-escalation
Only patients de-escalated during the acute/early phase were captured in the
analysis, as data regarding de-escalation on discharge is unknown

CONCLUSION
n= 13 De-escalation of P2Y12 Inhibitor Therapy
# of patients de-escalated

18/120

Clopidogrel dose given at time of de-escalation:
• 75 mg
• 300 mg
• 600 mg

7/18
9/18
2/18

Avg time (hours) between last dose of ticagrelor and first dose of
clopidogrel (range)

De-Escalation of P2Y12 Inhibitor Therapy
No

102
(85%)

18
(15%)

Yes

11:01 (01:59 – 19:11)

This was an observational project that was designed to evaluate prescribers’ preference
in P2Y12 inhibitor therapy for the initiation of DAPT after PCI. The results indicate that
ticagrelor was the preferred P2Y12 inhibitor in the majority of cases, with only a small
fraction being de-escalated to clopidogrel.
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